About Minerva Neurosciences, Inc.
https://www.minervaneurosciences.comMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
CEO
Remy Luthringer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-06-21 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FEDERATED HERMES, INC.
Shares:1.35M
Value:$5.85M
VANGUARD GROUP INC
Shares:252.03K
Value:$1.09M
RENAISSANCE TECHNOLOGIES LLC
Shares:116.5K
Value:$504.44K
Summary
Showing Top 3 of 25
About Minerva Neurosciences, Inc.
https://www.minervaneurosciences.comMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.84M ▼ | $-2.74M ▲ | 0% | $-0.36 ▲ | $-2.74M ▲ |
| Q2-2025 | $0 | $3.37M ▼ | $-3.26M ▲ | 0% | $-0.43 ▲ | $-3.26M ▲ |
| Q1-2025 | $0 | $3.9M ▼ | $-3.75M ▲ | 0% | $-0.5 ▲ | $-3.75M ▲ |
| Q4-2024 | $0 | $4.52M ▲ | $-4.27M ▼ | 0% | $-0.56 ▼ | $-4.27M ▼ |
| Q3-2024 | $0 | $4.37M | $22.51M | 0% | $2.97 | $22.52M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $12.29M ▼ | $28.09M ▼ | $62.67M ▲ | $-34.58M ▼ |
| Q2-2025 | $15.25M ▼ | $30.42M ▼ | $62.53M ▲ | $-32.11M ▼ |
| Q1-2025 | $17.29M ▼ | $32.8M ▼ | $61.95M ▼ | $-29.15M ▼ |
| Q4-2024 | $21.36M ▼ | $37.14M ▼ | $62.84M ▼ | $-25.69M ▼ |
| Q3-2024 | $26.53M | $42.81M | $64.48M | $-21.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.74M ▲ | $-2.92M ▼ | $0 | $-45.17K ▼ | $-2.96M ▼ | $-2.92M ▼ |
| Q2-2025 | $-3.26M ▲ | $-2.04M ▲ | $0 | $0 | $-2.04M ▲ | $-2.04M ▲ |
| Q4-2024 | $-4.27M ▼ | $-5.17M ▼ | $0 | $0 | $-5.17M ▼ | $-5.17M ▼ |
| Q3-2024 | $22.51M ▲ | $-4.35M ▼ | $0 | $0 | $-4.35M ▼ | $-4.35M ▼ |
| Q2-2024 | $-8.23M | $-3.94M | $0 | $0 | $-3.94M | $-3.94M |
CEO
Remy Luthringer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-06-21 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FEDERATED HERMES, INC.
Shares:1.35M
Value:$5.85M
VANGUARD GROUP INC
Shares:252.03K
Value:$1.09M
RENAISSANCE TECHNOLOGIES LLC
Shares:116.5K
Value:$504.44K
Summary
Showing Top 3 of 25